What the Levemir FlexTouch TV commercial - Que No Pase de Hoy is about.
Levemir FlexTouch is a type of insulin pen that helps diabetic patients control their blood sugar levels effectively. In the TV spot, 'Que No Pase de Hoy', the focus is on encouraging patients to take control of their diabetes and live life to the fullest, without letting the condition hold them back.
The ad features a variety of people living life to the fullest, despite having diabetes. There are shots of people surfing, hiking, dancing, and enjoying time with their loved ones. The ad highlights the challenges that diabetics face, but also emphasizes the importance of managing the condition effectively.
The voiceover in the ad emphasizes the need for patients to take their medication regularly and use Levemir FlexTouch as prescribed by their doctor. The ad also highlights the convenience of using the insulin pen, which is easy to use and can be taken anywhere. In the end, the message of the ad is clear - don't let diabetes hold you back from living your life to the fullest. With Levemir FlexTouch, you can manage your condition and enjoy life to the fullest.
Levemir FlexTouch TV commercial - Que No Pase de Hoy produced for
Levemir
was first shown on television on April 22, 2015.
Frequently Asked Questions about levemir flextouch tv spot, 'que no pase de hoy'
Novo Nordisk® discontinued manufacturing the Levemir® FlexTouch® in early February 2023. The FlexTouch® will be distributed until stock is depleted and is being replaced with the FlexPen®.
Levemir is a long-acting insulin analogue used as a basal insulin. Levemir is for subcutaneous administration only. Levemir must not be administered intravenously, as it may result in severe hypoglycaemia. Intramuscular administration should also be avoided.
To help address current supply anomalies, Novo Nordisk will be transitioning Levemir® from FlexTouch® to its original FlexPen® device, with the intent to alleviate strain on the manufacturing lines. This modification is being made as a result of the rising patient demand across the Novo Nordisk portfolio of products.
Levemir and Lantus are two long-acting insulins that share many similarities. They're similarly effective and can cause comparable side effects. The biggest difference between them is that Levemir may require twice-daily injections at lower doses. Lantus can typically be injected once a day at any dose.
Both Levemir and Lantus are preferred over NPH insulin because they have a longer duration of action, a less pronounced peak, and are more consistent in their effects with less risk of hypoglycemia. Both Levemir and Lantus are clear solutions, unlike NPH which requires resuspension prior to injection.
Levemir® is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.
Levemir® FlexTouch® will be discontinued as of early February 2023 and replaced by Levemir® FlexPen®, a slightly different type of prefilled pen. If you are currently taking Levemir®, you will notice that your pen looks slightly different when you pick it up from the pharmacy.
Same Insulin, Different Pen. Starting early February, Levemir® FlexTouch® (NDC: 0169-6438-10) is being phased out and replaced with Levemir® FlexPen® (NDC: 0169-6432-10). In order to minimize disruption, please make sure your patients have an updated prescription for Levemir® FlexPen® (NDC: 0169-6432-10).
They should not be used together but are usually included in a regimen with short or rapid-acting insulins. Although both Levemir and Lantus are long-acting insulins, one should not be substituted for the other except on a doctor's advice.
FlexTouch® and FlexPen® have different features and functions, and will require patients to adopt new Instructions For Use (IFU). However, the active medicine will not change with the conversion from FlexTouch® to FlexPen®, and it will not affect the efficacy and safety profile of Levemir®.
Insulin detemir injection (Levemir®): Pen and vial, throw away after 42 days.
Levemir is used to treat adults and children over the age of two with type 1 diabetes. It is also prescribed for adult patients with type 2 diabetes who are unable to achieve good glycemic control on oral hypoglycemics alone.
